

# 11<sup>th</sup> World Heart Congress

July 21-22, 2022 | Webinar

Volume: 11

## New therapies in lipid management – 2022

### Alnoor Abdulla

Cardiology Education Consultant & Medical Navigation, Canada

Higher levels of atherogenic lipoproteins (LDL, Non HDL Cholesterol, ApoB, Lp(a)) and Triglycerides have been shown to increase Cardiovascular morbidity and mortality. Lowering levels of these decreases this morbidity and mortality. STATINS reduce LDL, Non HDL & ApoB levels and significantly improve adverse cardiovascular outcomes. However Statins have limitations. These include real and perceived side effects, suboptimal adherence, suboptimal pharmacodynamics and their inability to lower LDL to low enough target levels required in high risk patients. This results in continuing residual lipid risk. Additionally Statins do not reduce Lp(a) & Triglyceride levels significantly.

This has led to the development of medications which can be used in combination with or instead of maximally tolerated doses of Statins to address this residual cardiovascular lipid risk. This presentation will review the presently available therapies in addition to Statins, their impact on hard cardiovascular outcomes and then briefly discuss the newer advances in therapy that are going to be available in the near future.

### Biography

Alnoor Abdulla, Associate professor at University of Ottawa Heart Institute and Cardiology Education Consultant & Medical Navigation, Canada.

abdulla@cardiaccare.ca